# reload+after+2024-01-20 06:44:49.421188
address1§200 Inner Belt Road
address2§Suite 400
city§Somerville
state§MA
zip§02143
country§United States
phone§617 229 6499
website§https://www.finchtherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
fullTimeEmployees§18
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Matthew P. Blischak J.D.', 'title': 'Chief Executive Officer', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Lance  Thibault CPA', 'age': 57, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James S. Sigler MBA', 'age': 62, 'title': 'Executive Vice President of CMC', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.415
priceToSalesTrailing12Months§48.1728
currency§USD
dateShortInterest§1702598400
forwardEps§-20.59
exchange§NMS
quoteType§EQUITY
shortName§Finch Therapeutics Group, Inc.
longName§Finch Therapeutics Group, Inc.
firstTradeDateEpochUtc§1616160600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b8e86349-7dce-3756-a76c-43df24d3f738
gmtOffSetMilliseconds§-18000000
targetHighPrice§90.0
targetLowPrice§90.0
targetMeanPrice§90.0
targetMedianPrice§90.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§5.899
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
